Clinical Trial Update: Long Term Extension Study in Patients With Primary Hyperoxaluria [Phase 3]

View source ↗

Summary

A Phase 3 long-term extension study in patients with Primary Hyperoxaluria is ongoing but not recruiting, sponsored by Dicerna Pharmaceuticals (a Novo Nordisk c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Drugs mentioned

• DCR-PH1 (DCR-PH1)

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) | Phase 3 | Status: ACTIVE_NOT_RECRUITING